Bedaquiline Dry Powder Inhalation via Spray Drying
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral administration of bedaquiline for tuberculosis treatment lacks effective delivery to the lungs, limiting its therapeutic efficacy for pulmonary tuberculosis.
Innovation Solution
A bedaquiline pharmaceutical preparation is developed using a solid composition of bedaquiline, amino acid, phospholipid, and polylactic acid, processed by spray drying to produce spherical particles with controlled sizes <5 μm, enabling better aerodynamics and inhalation delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bedaquiline is administered orally, then the drug can be delivered systemically, but effective delivery to the lungs is insufficient
Solution Approach 1:
The patent changes the physical parameters of bedaquiline by converting it from conventional oral dosage forms to inhalable dry powder particles with specific size ranges (0.5-5 μm). This parameter change enables direct pulmonary delivery, improving therapeutic efficacy for tuberculosis while maintaining ease of administration through inhalation.
Solution Approach 2:
The patent utilizes phase transition by converting bedaquiline from a dissolved state in solution to a solid particulate state through spray drying. This phase transition creates dry powder inhalation formulation that can be directly delivered to the lungs, resolving the contradiction between systemic delivery and pulmonary targeting.
2Ease of manufacture
If particles are produced by grinding, then the drug can be processed, but irregular shapes are produced which reduce aerodynamics
Solution Approach 1:
The patent replaces the mechanical grinding system with a spray drying system that uses fluid dynamics and phase transition. This substitution produces particles with spherical shapes and controlled size distributions through atomization and rapid drying, eliminating the irregular shapes associated with mechanical grinding while maintaining manufacturing feasibility.
3Ease of manufacture
If particle sizes are not controlled, then the formulation is simpler, but lung distribution and therapeutic effect are reduced
Solution Approach 1:
The patent introduces dynamic control of particle size through adjustable spray drying parameters including spray rate, drying temperature, and atomization pressure. This dynamic approach allows optimization of particle size distribution (0.5-5 μm) for pulmonary delivery while maintaining relatively simple formulation processes, resolving the contradiction between manufacturing simplicity and lung distribution efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The preparation achieves enhanced lung distribution and therapeutic effect by extending the flight distance of fine particles, with optimized particle sizes and shapes improving pulmonary drug delivery and retention.
Implementation Method 1
spray drying the solution obtained from step a to obtain fine particles
Implementation Method 2
an ultrasonic atomization percentage is 40 ̃80%
Data Source
AI summary
A pharmaceutical composition for dry powder inhalation includes an active ingredient and a first pharmacologically acceptable excipient. The active ingredient includes bedaquiline or a pharmaceutically acceptable salt thereof. The first pharmacologically acceptable excipient includes amino acid, polysaccharide, phospholipid, polylactic acid, polylactic acid copolymer, or a combination thereof. A method of preparing a pharmaceutical composition for dry powder inhalation is also provided.